INTRODUCTION: Neoadjuvant chemoradiation (CRT) confers a survival benefit in locally advanced @entity418 . The optimal dose of radiotherapy remains undefined. METHODS: From a prospective database, we identified @entity1 who received CRT followed by Ivor Lewis esophagectomy. Surgical complications, pathological response, and oncological outcome were compared between @entity1 who received a radiotherapy (RT) dose of 36 Gy (group 1) versus a dose of > 40 Gy (group 2). RESULTS: 147 @entity1 were evaluated : 109 received 36 Gy, while 38 received 41-50 Gy. Mean age was 61    9 years (84% male). Median hospital stay was 16 days. @entity834 occurred in 4.0%. @entity358 occurred in 41.8%, neither being influenced by RT dose. Complete resection (R0) was achieved in 95% (group 1) and 100% (group 2), P = 0.3. Pathological complete response (pCR) was observed in 19% (group 1) and 37% (group 2), P = 0.04. Local recurrence developed in 9% in group 1, and 3% in group 2 (P = 0.3), but regional recurrence developed significantly higher in the low dose group (28% vs 3%, P < 0.001). Metastatic recurrence occurred in 48% in group 1 and 13% in group 2 (P < 0.001). CONCLUSIONS: In @entity1 with locally advanced @entity418 a higher RT dose does not affect surgical outcome, enhances pCR rate, and reduces the locoregional and metastatic recurrence risk.

Effect of neoadjuvant radiation dose on surgical and oncological outcome in locally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity358 :: ('MESH:D008171', 'Disease') :: ['Pulmonary complications'] @entity834 :: ('MESH:D057868', 'Disease') :: ['Anastomotic leakage'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer']
@entity418 :: (MESH:D004938,Disease) :: ['esophageal cancer']
